Skip to content

The impact of pHA130 blood perfusion combined with hemodialysis on cardiovascular events in patients with end-stage renal disease.

The impact of pHA130 blood perfusion combined with hemodialysis on cardiovascular events in patients with end-stage renal disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091864
Enrollment
Unknown
Registered
2024-11-05
Start date
2024-11-08
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Research group

Interventions

control group:NA

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 75 years with end-stage renal disease (ESRD) who are undergoing regular maintenance hemodialysis treatment at the Affiliated Hospital of Xuzhou Medical University. 2. Patients must be receiving regular hemodialysis, 3 times per week, 4 hours per session, for at least 3 months. 3. Patients must be willing and able to comply with the requirements of the study protocol and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients aged =18 years or =75 years. 2. Patients undergoing combined hemodialysis and peritoneal dialysis. 3. Patients with known allergic reactions, contraindications, or inability to tolerate dialysis materials. 4. Patients with acute severe infections, severe cardiopulmonary dysfunction, severe cerebrovascular disease, severe bleeding tendencies or active bleeding, malignancies, etc. 5. Other conditions that the researchers deem inappropriate for inclusion in this study.

Design outcomes

Secondary

MeasureTime frame
electrolyte;blood routine examination;Lipid metabolism;

Primary

MeasureTime frame
The rate of decline of indoleate sulfate in the body;The rate of decline of p-cresyl sulfate in the body;The rate of decline of PTH in the body;The rate of decline of ß2-MG in the body;The rate of decline of homocysteine in the body;

Countries

China

Contacts

Public ContactSun Dong

Affiliated Hospital of Xuzhou Medical University

sundong126@yahoo.com+86 180 5226 8639

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026